Literature DB >> 35414136

Improving the reporting of economic evaluation in osteoporosis: the value of CHEERS 2022 statement.

M Hiligsmann1, N Li2, C Cooper3, J-Y Reginster4, S Silverman5, C Carswell6, D Husereau7,8.   

Abstract

Entities:  

Year:  2022        PMID： 35414136     DOI： 10.1007/s00198-022-06400-3

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   5.071


× No keyword cloud information.
  9 in total

1.  Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women.

Authors:  Smita Nayak; Mark S Roberts; Susan L Greenspan
Journal:  Ann Intern Med       Date:  2011-12-06       Impact factor: 25.391

2.  Economic impact and cost-effectiveness of fracture liaison services: a systematic review of the literature.

Authors:  C-H Wu; I-J Kao; W-C Hung; S-C Lin; H-C Liu; M-H Hsieh; S Bagga; M Achra; T-T Cheng; R-S Yang
Journal:  Osteoporos Int       Date:  2018-02-19       Impact factor: 4.507

Review 3.  A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis.

Authors:  Mickaël Hiligsmann; Silvia M Evers; Wafa Ben Sedrine; John A Kanis; Bram Ramaekers; Jean-Yves Reginster; Stuart Silverman; Caroline E Wyers; Annelies Boonen
Journal:  Pharmacoeconomics       Date:  2015-03       Impact factor: 4.981

4.  The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study.

Authors:  David A Turner; Rebekah Fong Soe Khioe; Lee Shepstone; Elizabeth Lenaghan; Cyrus Cooper; Neil Gittoes; Nicholas C Harvey; Richard Holland; Amanda Howe; Eugene McCloskey; Terence W O'Neill; David Torgerson; Richard Fordham
Journal:  J Bone Miner Res       Date:  2018-02-22       Impact factor: 6.741

5.  Cost-effectiveness of Screening for Osteoporosis in Older Men With a History of Falls.

Authors:  Kouta Ito
Journal:  JAMA Netw Open       Date:  2020-12-01

6.  Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy.

Authors:  M Hiligsmann; S Maggi; N Veronese; L Sartori; J-Y Reginster
Journal:  Osteoporos Int       Date:  2021-01-14       Impact factor: 4.507

7.  Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation.

Authors:  M Hiligsmann; J-Y Reginster; A N A Tosteson; S V Bukata; K G Saag; D T Gold; P Halbout; F Jiwa; E M Lewiecki; D Pinto; J D Adachi; N Al-Daghri; O Bruyère; M Chandran; C Cooper; N C Harvey; T A Einhorn; J A Kanis; D L Kendler; O D Messina; R Rizzoli; L Si; S Silverman
Journal:  Osteoporos Int       Date:  2018-10-31       Impact factor: 4.507

8.  Predicting the intervention threshold for initiating osteoporosis treatment among postmenopausal women in China: a cost-effectiveness analysis based on real-world data.

Authors:  L Cui; T He; Y Jiang; M Li; O Wang; R Jiajue; Y Chi; Q Xu; X Xing; W Xia
Journal:  Osteoporos Int       Date:  2019-11-21       Impact factor: 4.507

9.  An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis.

Authors:  Nannan Li; Dennis Cornelissen; Stuart Silverman; Daniel Pinto; Lei Si; Ingrid Kremer; Sandrine Bours; Robin de Bot; Annelies Boonen; Silvia Evers; Joop van den Bergh; Jean-Yves Reginster; Mickaël Hiligsmann
Journal:  Pharmacoeconomics       Date:  2020-10-07       Impact factor: 4.981
  9 in total
  1 in total

1.  The interdisciplinary fracture liaison service improves health-related outcomes and survival of older adults after hip fracture surgical repair.

Authors:  Carmelinda Ruggiero; Marta Baroni; Giuseppe Rocco Talesa; Alessandro Cirimbilli; Valentina Prenni; Valentina Bubba; Luca Parretti; Riccardo Bogini; Giuliana Duranti; Auro Caraffa; Virginia Boccardi; Patrizia Mecocci; Giuseppe Rinonapoli
Journal:  Arch Osteoporos       Date:  2022-10-17       Impact factor: 2.879
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.